Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition
Affiliations: Department of Radiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China, Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE‑171 77 Stockholm, Sweden, Cancer Hospital of China Medical University and Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Department of Gastrointestinal Surgery, Guang'an People's Hospital, Guang'an, Sichuan 638001, P.R. China, Department of Radiotherapy and Oncology, The First Affiliated Hospital of Chongqing University, Chongqing 400016, P.R. China, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE‑171 77 Stockholm, Sweden, Department of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi, Hubei 445000, P.R. China
- Published online on: December 3, 2020 https://doi.org/10.3892/or.2020.7881
- Pages: 459-468
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.